Increasing the visibility for scientists with different gender identities or sexual orientations (LGBTQ+) – that is the goal for the first Pride Symposium at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC). On July 22, 2022, the organizers want to inform colleagues in the scientific community, as well as citizens and journalists from Berlin, and exchange ideas on topics that are particularly relevant for the LGBTQ+ community in the life and other sciences.
The program of the mini symposium includes four expert presentations followed by a panel discussion on the visibility of queer people in science, transgender access to health care, and why there is little research on queer issues in the natural sciences. Invited speakers includefrom the Leibniz Institute of Vegetable and Ornamental Crops, from the University of Toronto, and from Charité – Universitätsmedizin Berlin. , working group leader at the MDC, will join as well.
When and where?
The Pride Symposium will take place on Friday, July 22, 2022, from 3:30 to 5:30 p.m. in the Large Conference Room at the Berlin Institute for Medical Systems Biology (BIMSB) of the MDC at Hannoversche Straße 28 in Berlin-Mitte. Lectures and discussions will be in English only;is required.
- Event: (in English)
Jacobo López Carballo
Co-Organizer of the Pride Symposium, PhD student in the AG Gotthardt
+49 30 9406-3272
Editor, Communications Department
Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
+49 (0)30 9406-2118
The Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) is one of the world’s leading biomedical research institutions. Max Delbrück, a Berlin native, was a Nobel laureate and one of the founders of molecular biology. At the MDC’s locations in Berlin-Buch and Mitte, researchers from some 60 countries analyze the human system – investigating the biological foundations of life from its most elementary building blocks to systems-wide mechanisms. By understanding what regulates or disrupts the dynamic equilibrium in a cell, an organ, or the entire body, we can prevent diseases, diagnose them earlier, and stop their progression with tailored therapies. Patients should benefit as soon as possible from basic research discoveries. The MDC therefore supports spin-off creation and participates in collaborative networks. It works in close partnership with Charité – Universitätsmedizin Berlin in the jointly run Experimental and Clinical Research Center (ECRC), the Berlin Institute of Health (BIH) at Charité, and the German Center for Cardiovascular Research (DZHK). Founded in 1992, the MDC today employs 1,600 people and is funded 90 percent by the German federal government and 10 percent by the State of Berlin.